Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt 0.15
ZTS's Cash to Debt is ranked lower than
74% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.03 vs. ZTS: 0.15 )
Ranked among companies with meaningful Cash to Debt only.
ZTS' s 10-Year Cash to Debt Range
Min: 0.1   Max: N/A
Current: 0.15

Equity to Asset 0.20
ZTS's Equity to Asset is ranked lower than
61% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.43 vs. ZTS: 0.20 )
Ranked among companies with meaningful Equity to Asset only.
ZTS' s 10-Year Equity to Asset Range
Min: 0.12   Max: 0.69
Current: 0.2

0.12
0.69
Interest Coverage 8.07
ZTS's Interest Coverage is ranked higher than
66% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. ZTS: 8.07 )
Ranked among companies with meaningful Interest Coverage only.
ZTS' s 10-Year Interest Coverage Range
Min: 2.3   Max: 13.28
Current: 8.07

2.3
13.28
F-Score: 6
Z-Score: 4.51
M-Score: -2.67
WACC vs ROIC
7.54%
16.00%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 19.73
ZTS's Operating margin (%) is ranked higher than
86% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.69 vs. ZTS: 19.73 )
Ranked among companies with meaningful Operating margin (%) only.
ZTS' s 10-Year Operating margin (%) Range
Min: -4.53   Max: 19.73
Current: 19.73

-4.53
19.73
Net-margin (%) 12.38
ZTS's Net-margin (%) is ranked higher than
80% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.76 vs. ZTS: 12.38 )
Ranked among companies with meaningful Net-margin (%) only.
ZTS' s 10-Year Net-margin (%) Range
Min: -3.62   Max: 12.18
Current: 12.38

-3.62
12.18
ROE (%) 47.14
ZTS's ROE (%) is ranked higher than
96% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.48 vs. ZTS: 47.14 )
Ranked among companies with meaningful ROE (%) only.
ZTS' s 10-Year ROE (%) Range
Min: 11.26   Max: 51.8
Current: 47.14

11.26
51.8
ROA (%) 9.13
ZTS's ROA (%) is ranked higher than
79% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. ZTS: 9.13 )
Ranked among companies with meaningful ROA (%) only.
ZTS' s 10-Year ROA (%) Range
Min: 7.28   Max: 8.86
Current: 9.13

7.28
8.86
ROC (Joel Greenblatt) (%) 32.16
ZTS's ROC (Joel Greenblatt) (%) is ranked higher than
80% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.04 vs. ZTS: 32.16 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ZTS' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 25.88   Max: 36.32
Current: 32.16

25.88
36.32
Revenue Growth (3Y)(%) 4.00
ZTS's Revenue Growth (3Y)(%) is ranked higher than
64% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -5.40 vs. ZTS: 4.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ZTS' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 8.4
Current: 4

0
8.4
EBITDA Growth (3Y)(%) 21.40
ZTS's EBITDA Growth (3Y)(%) is ranked higher than
87% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -31.90 vs. ZTS: 21.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ZTS' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: 36.2
Current: 21.4

0
36.2
EPS Growth (3Y)(%) 33.30
ZTS's EPS Growth (3Y)(%) is ranked higher than
92% of the 834 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -53.60 vs. ZTS: 33.30 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ZTS' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: 66.2
Current: 33.3

0
66.2
» ZTS's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ZTS Guru Trades in Q3 2014

Bill Ackman 5,536,862 sh (New)
John Keeley 79,504 sh (+6.71%)
Robert Olstein 178,000 sh (unchged)
Vanguard Health Care Fund 10,798,417 sh (unchged)
Pioneer Investments 2,203,980 sh (unchged)
Joel Greenblatt Sold Out
First Eagle Investment 2,174,162 sh (-0.13%)
Ruane Cunniff 173,322 sh (-0.14%)
RS Investment Management 2,491,074 sh (-2.27%)
George Soros 4,031,735 sh (-8.09%)
Mario Gabelli 217,980 sh (-10.29%)
» More
Q4 2014

ZTS Guru Trades in Q4 2014

Jim Simons 650,500 sh (New)
Steven Cohen 1,718,300 sh (New)
Bill Ackman 41,569,646 sh (+650.78%)
Mario Gabelli 626,893 sh (+187.59%)
George Soros 4,106,735 sh (+1.86%)
Ruane Cunniff 173,423 sh (+0.06%)
Bill Ackman 41,823,145 sh (unchged)
Pioneer Investments 2,202,773 sh (-0.05%)
Vanguard Health Care Fund 9,178,657 sh (-15.00%)
Robert Olstein 141,000 sh (-20.79%)
John Keeley 62,164 sh (-21.81%)
First Eagle Investment 820,467 sh (-62.26%)
RS Investment Management 212,262 sh (-91.48%)
» More
Q1 2015

ZTS Guru Trades in Q1 2015

Paul Tudor Jones 8,800 sh (New)
Louis Moore Bacon 55,000 sh (New)
Caxton Associates 100,000 sh (New)
Jim Simons 1,822,794 sh (+180.21%)
Pioneer Investments 2,879,512 sh (+30.72%)
Bill Ackman 41,823,145 sh (+0.61%)
First Eagle Investment 820,467 sh (unchged)
Robert Olstein 141,000 sh (unchged)
George Soros 4,106,735 sh (unchged)
Bill Ackman 41,823,145 sh (unchged)
RS Investment Management Sold Out
John Keeley 61,856 sh (-0.50%)
Mario Gabelli 614,785 sh (-1.93%)
Ruane Cunniff 139,936 sh (-19.31%)
Vanguard Health Care Fund 6,175,407 sh (-32.72%)
Steven Cohen 142,400 sh (-91.71%)
» More
2015

ZTS Guru Trades in 2015

Bill Ackman 41,823,145 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with ZTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK